Pfizer Inc. Stock
€22.03
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | -0.070% | -1.454% | -1.277% | -9.119% | -13.185% | -55.523% | -35.077% |
| Johnson & Johnson | 0.800% | 4.004% | 7.476% | 29.048% | 29.623% | 6.826% | 42.830% |
| Elanco Animal Health Inc. | 1.010% | -3.542% | -4.647% | 50.974% | 57.066% | 51.226% | -23.307% |
| Biogen Inc. | 0.890% | -4.751% | 6.420% | -0.034% | 2.985% | -46.201% | -25.564% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
Forget Teladoc and Buy This Healthcare Stock Instead
Telemedicine leader Teladoc Health (NYSE: TDOC) has been struggling for several years. The company's services are no longer experiencing the kind of demand they did during the pandemic years
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.
It now seems so long ago that Pfizer (NYSE: PFE) became the first company in the biopharmaceutical industry to generate over $100 billion in annual sales. The drugmaker achieved this milestone
The Best Turnaround Stock to Invest $1,000 in Right Now
Even very well-run companies will eventually fall upon hard times. That's the backstory you need to keep in mind when you examine Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE). Here's why